Results 111 to 120 of about 104,861 (298)

2‐Azaazulenium Hemicyanine Dyes for NIR‐II Multimodal Imaging and Combined Phototherapy

Angewandte Chemie, EarlyView.
A strategically engineered class of 2‐azaazulenium hemicyanines is developed, featuring bright fluorescence in the second near‐infrared (NIR‐II) window and multifunctional performance. SWJT‐OCH3 shows type I/II reactive oxygen species (ROS) generation and excellent photothermal activity.
Min Peng, Bing‐Ya Wang, Hai Xu, Qiang Wang, Rong‐Dan Xiao, Rui Tan, Yu Peng, Ya‐Wen Wang, Juyoung Yoon   +8 more
wiley   +2 more sources

Inhibition of Poly(ADP-Ribose) polymerase enhances the toxicity of 131I-Metaiodobenzylguanidine/Topotecan combination therapy to cells and xenografts that express the noradrenaline transporter [PDF]

, 2012
Targeted radiotherapy using [131I]meta-iodobenzylguanidine ([131I]MIBG) has produced remissions in some neuroblastoma patients. We previously reported that combining [131I]MIBG with the topoisomerase I (Topo-I) inhibitor topotecan induced long-term DNA ...
Babich, John W, Boyd, Marie, Champion, Sue, Gaze, Mark N, Mairs, Robert J, McCluskey, Anthony G, Pimlott, Sally L, Tesson, Mathias   +7 more
core   +1 more source

Cuproptosis and Mitophagy Mediated by the THUMPD1/IGF2R‐Dependent Suppression of AKT and Activation of AMPK Signaling Suppress Lung Adenocarcinoma Progression

Advanced Science, EarlyView.
THUMPD1 drives a tumor‐suppressive signaling cascade in lung adenocarcinoma by promoting IGF2R expression. IGF2R associates with PPP2R1A to suppress AKT and activate AMPK, leading to SLC31A1 upregulation and copper accumulation. Elevated copper disrupts mitochondrial metabolism and induces excessive mitophagy, thereby restraining tumor growth and ...
Kai Wu, Bo Qin, Zhuoyu Gu, Weizheng Ding, Xiaoming Chen, Kaishang Zhang, Yujin Qiao, Shuang Yuan, Song Zhao, Xiangnan Li, Peng Zhang   +10 more
wiley   +1 more source

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [PDF]

, 2017
Background: Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Aghajanian, C, Aghajanian, Carol, Amit, A, Armstrong, D K, Armstrong, Deborah K, Banerjee, S N, Birrer, M J, Bologna, A, Buck, M, Buss, M K, Cameron, Terri, Chambers, S K, Chen, L-m, Clamp, A, Clamp, Andrew, Coleman, R L, Coleman, Robert L, Colombo, N, Colombo, Nicoletta, Dean, A, Dean, Andrew, Denys, H, Dirix, L, Drew, Y, El-Balat, A, Elit, L, Floquet, A, Floquet, Anne, Fong, P C, Fong, Peter C, Friedlander, M L, Gabra, H G, Gancedo, M Amenedo, Gancedo, Margarita Amenedo, Garcia-Donas, J, Garcia-Donas, Jesus, Ghatage, P, Giordano, Heidi, Gladieff, L, Goble, Sandra, Goh, J C, Goh, Jeffrey C, Grace, Caroline, Guerra, E M, Harding, Thomas C, Harnett, P, Herraez, A Casado, Holloway, R W, Holloway, Robert W, Hänle, C, Isaacson, Jeff, Jackson, D, Joly, F, Kichenadasse, G, Konecny, G E, Konecny, Gottfried E, Kovel, S, Krabisch, P, Leary, A, Leary, Alexandra, Ledermann, J A, Ledermann, Jonathan A, Leviov, M, Lin, Kevin K, Lortholary, A, Lorusso, D, Lorusso, Domenica, Lotz, J, Ma, L, Maloney, Lara, McNeish, I A, McNeish, Iain A, Medioni, J, Morgan, M A, Morris, R T, Mutch, D G, Neunhöffer, T, O'Donnell, A, O'Malley, D M, O'Malley, David M, Oaknin, A, Oaknin, Ana, Oza, A M, Oza, Amit M, Palacio, I, Parkinson, C, Pignata, S, Plante, M, Powell, M, Provencher, D, Pölcher, M, Raponi, Mitch, Romero, I, Sabbatini, R F, Safra, T, Sanchez, A, Scambia, G, Scambia, Giovanni, Scott, C L, Scott, Clare L, Shapira-Frommer, R, Slomovitz, B M, Stemmer, S, Sun, James, Swisher, E M, Swisher, Elizabeth M, Tamberi, S, Tredan, O, Vanderkwaak, T, Vergote, I, Vulfovich, M, Weberpals, J I, Weberpals, Johanne I, Welch, S, Wimberger, P, You, B, Zamagni, C   +116 more
core   +1 more source

Clinical approaches to overcome PARP inhibitor resistance

Molecular Cancer
PARP inhibitors have profoundly changed treatment options for cancers with homologous recombination repair defects, especially those carrying BRCA1/2 mutations.
Yutian Zou, Hanqi Zhang, Pangzhou Chen, Jiayi Tang, Siwei Yang, Christophe Nicot, Ziyun Guan, Xing Li, Hailin Tang   +8 more
doaj   +1 more source

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.

PLoS ONE, 2015
Ewing's sarcoma is a malignant pediatric bone tumor with a poor prognosis for patients with metastatic or recurrent disease. Ewing's sarcoma cells are acutely hypersensitive to poly (ADP-ribose) polymerase (PARP) inhibition and this is being evaluated in
Sonja J Gill, Jon Travers, Irina Pshenichnaya, Fiona A Kogera, Syd Barthorpe, Tatiana Mironenko, Laura Richardson, Cyril H Benes, Michael R Stratton, Ultan McDermott, Stephen P Jackson, Mathew J Garnett   +11 more
doaj   +1 more source

Vorinostat Potentiates Chemoimmunotherapy in Immune‐Enriched Pancreatic Cancer

Advanced Science, EarlyView.
Immune‐enriched pancreatic cancer does not confer a significant survival advantage. SAHA sensitizes these “hot” tumors to chemoimmunotherapy by disrupting a FASN/PARP9‐driven “metabolic trap” and enhancing CD8+ T cell function. A CD8high/FASNhigh/PARP9high signature identifies patients who are most likely to benefit from the “gemcitabine‐nivolumab‐SAHA”
Chen Chen, Dingru Li, Yingna Liao, Zehua Wang, Chunbin Zhu, Zifeng Zhang, Liquan Jin, Yueyue Chen, Jiaoshun Chen, Junyi Xu, Miaoyan Wei, Rong Tang, Xianjun Yu, Si Shi   +13 more
wiley   +1 more source

Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas [PDF]

, 2018
FDA-approved BRAF inhibitors produce high response rates and improve overall survival in patients with BRAF V600E/K-mutant melanoma, but are linked to pathologies associated with paradoxical ERK1/2 activation in wild-type BRAF cells.
Aplin, Andrew E., Berger, Adam C., Bollag, Gideon, Davies, Michael A., Goldberg, Allison F., Hartsough, Edward J., Knudsen, Karen E., Kugel, Curtis H., Purwin, Timothy J., Schiewer, Matthew J., Vido, Michael J.   +10 more
core   +1 more source

Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Diabetic Retinopathy: An Attractive but Elusive Choice for Drug Development

Pharmaceutics
Owing to its promiscuous roles, poly (ADP-ribose) polymerase-1 (PARP-1) is involved in various neurological disorders including several retinal pathologies.
Etelka Pöstyéni, Róbert Gábriel, Andrea Kovács-Valasek   +2 more
doaj   +1 more source

Detachment‐Induced FAK‐STAT3‐NNMT Inhibits CTCs Anoikis to Promote Breast Cancer Metastasis by Enhancing Fatty Acid Oxidation

Advanced Science, EarlyView.
The FAK‐STAT3‐NNMT axis drives anoikis resistance in circulating tumor cells by reprogramming fatty acid oxidation. Targeting this metabolic vulnerability suppresses metastasis, untangling a key mechanism of breast cancer progression and revealing NNMT as a promising therapeutic target.
Qingchao Tong, Yilei Ma, Yuzhen Gao, Lin Zhou, Luping Lou, Qiang Fang, Sining Fang, Ru Zhao, Jin Zeng, Jun Yang, Guoli Li, Xinyou Xie, Yanzhong Wang, Jun Zhang   +13 more
wiley   +1 more source